In intensive broiler and swine production, Jinye Qingwen Powder Veterinary Grade API is most frequently incorporated into a fully water-miscible powder intended for proportional dosing through medication tanks and nipple drinker lines. The formulation addition window for the API in a 5 kg water-soluble powder batch is typically maintained between 0.3 wt% and 1.0 wt% of the total dry blend, with the remainder composed of anhydrous dextrose or spray-dried lactose as the carrier, 0.2–0.5 wt% citric acid monohydrate as the acidifier, and 0.1–0.3 wt% polyvinylpyrrolidone K-30 as the dispersion aid; the exact API fraction is adjusted against the target species dose, sulfate ash content of the carrier, and the mix-line recovery specification. Because the raw extract is derived from seasonal botanical material, batch-to-batch variance in extractable solids and sulfate ash is monitored by near-infrared reflectance at the receiving dock, with a NIR moisture target of 3.0–4.5 wt% enforced before blending. Downstream production for this presentation is a three-stage dry blending operation: the API is first pre-mixed with an equal mass of the carrier in a 200 L V-blender at 15 rpm for 12–15 min, then discharged into a 1,000 L ribbon blender for the main blend at 28–32 rpm, and finally passed through a 60-mesh oscillating sieve to remove agglomerates formed by hygroscopic extract fractions. On production-scale lines, electrostatic adhesion of the extract powder to polyvinyl chloride gaskets and transparent sight-glass panels has been observed when ambient relative humidity falls below 30%, causing active content drift in the first three discharge fractions; therefore the blending room is usually maintained at 40–55% RH and 18–25 °C, and the blender is grounded through a ≤10⁶ Ω resistance path. The finished product is tested for loss on drying, active marker content uniformity across ten sampling points, and dissolution performance in 1 L of hard water at 25 °C; the release criterion is typically a dissolution of not less than 90% within 15 min by the paddle method at 50 rpm. The applicable compliance framework includes Chinese Veterinary Pharmacopoeia CVP 2020 General Chapter 0105 for powders, VICH GL18 for residual solvent limits in botanical extract processing, and the manufacturing authorization provisions of EU Regulation 2019/6 for veterinary medicinal products. Terminal finished product types are 100 g, 500 g, 1 kg, and 5 kg laminated foil pouches labeled for oral solution reconstitution, with a maximum dry storage shelf-life of 24 months at ≤25 °C and ≤60% RH.

How Does Feed Premix Dilution Affect Homogeneity and Blend Carryover in High-Throughput Mills?

At feed mills processing 20–40 t/h compound feed, the API is seldom added directly to the final feed; it is first diluted into a 0.5–1.0 wt% intermediate premix on a calcium carbonate or wheat bran carrier, and that premix is then metered into the main mixer at an inclusion rate of 0.5–2.0 kg/t of finished feed. The API load in the intermediate premix is normally held between 1.5 wt% and 3.0 wt%, with the upper boundary determined by dust generation and the lower boundary by the analytical limit of quantification for the marker in finished feed. Production of the intermediate premix takes place in a twin-shaft paddle mixer with a working capacity of 2,000 kg and a mixing time of 180–240 s; the coefficient of variation for marker distribution is controlled at ≤5% across ten sampling points, and carryover into the next batch is reduced by pneumatically cleaning the mixer after each run. A particular bottleneck on high-capacity lines is the segregation of fine extract particles during pneumatic transfer to the main feed mixer; therefore the premix is discharged by gravity or dense-phase conveying at 0.5–1.5 bar rather than dilute-phase air flow, which can strip the active fraction from the carrier. The applicable standards are GB/T 5916-2020 for formula feed classification and labeling, GB/T 16764-2006 for hygiene requirements in feed mills, and EU Regulation 2017/625 on official controls for feed additives imported into the European market. Terminal product types include 5 kg, 10 kg, and 25 kg multi-wall paper bags with an inner polyethylene liner, as well as 1 t flexible intermediate bulk containers for integrated swine and poultry sites.

Rumen-Stable Tablet Compression and the Moisture Uptake Threshold

Tablet compression of the spray-dried extract powder is constrained by the hygroscopicity of residual polysaccharide and polyphenolic fractions; when the powder moisture content exceeds 5.0 wt%, granulation sticks to the die wall and tablet weight variability exceeds the pharmacopoeial limit. The addition ratio of the API in a direct-compression tablet core is typically 8.0–12.0 wt%, combined with 35–45 wt% microcrystalline cellulose PH102, 20–30 wt% lactose monohydrate, 3–5 wt% croscarmellose sodium, and 0.5–1.0 wt% magnesium stearate; the core is then film-coated with a 3–5 wt% hydroxypropyl methylcellulose-based coating to mask bitterness and reduce moisture ingress during bulk storage. The compression step is executed on a 27-station rotary tablet press with a turret speed of 40–60 rpm, a pre-compression force of 8–12 kN, and a main compression force of 25–40 kN; target tablet hardness is 60–100 N for 1 g tablets and 80–150 N for 5 g veterinarian-style oral boluses, while friability is held at ≤1.0% per CVP 2020 General Chapter 0101. A field-observed failure mode on production batches is edge chipping when the upper punch penetration is set too deep or when granule particle size distribution contains more than 20% fines below 75 µm; therefore dry granulation by roller compaction at 3–5 kN/cm roll force is used for API lots with a Carr index above 30. Compliance for tablets intended for food-producing species requires residue depletion data under EU Regulation 2019/6, and for export to Asia, CVP 2020 General Chapter 0101 uniformity of dosage units is applied. Terminal finished product types include film-coated 1 g and 5 g tablets for oral administration, 10 g gelatin-coated boluses for cattle, and 20 g large-animal boluses packed in blister strips.

For liquid dosage forms intended for metering line distribution, the API is dispersed in a buffered aqueous vehicle rather than dry blended; the final formulation is a suspension/solution hybrid with an API addition level of 2.0 wt/vol% to 5.0 wt/vol%, depending on whether the preparation is used as a short-duration therapeutic drench or a longer-duration continuous drinking-water medication. The vehicle comprises 60–70 vol% purified water, 10–15 vol% propylene glycol, 5–10 vol% glycerin, 0.2–0.5 wt/vol% sodium benzoate, and 0.05–0.1 wt/vol% disodium edetate as a chelating agent; the pH is adjusted to 5.0–6.5 with citric acid or sodium citrate to suppress oxidative degradation of the polyphenolic fraction. Downstream production uses a high-shear dispersion vessel with a bottom-mounted rotor-stator at 3,000 rpm for 20–30 min, followed by a 0.45 µm polypropylene bag filter for clarification and a plate heat exchanger for cooling to ≤20 °C before filling. The principal process risk is sedimentation of insolubilized calcium salts from hard water or phytosterol agglomerates; this is managed by a 1–2 wt/vol% microcrystalline cellulose/sodium carboxymethyl cellulose co-processed suspending agent and by re-circulation through a colloid mill at 0.2–0.5 mm rotor-stator gap. The applicable standards are CVP 2020 General Chapter 0106 for oral solutions, ICH Q6A specification guidelines for new drug substances, and EU Regulation 2019/6 for veterinary product authorization when the solution is sold as a ready-to-use medicine. Terminal finished product types are 5 L, 10 L, and 20 L high-density polyethylene jerricans with a tamper-evident cap, as well as 1 L bottles for smaller swine and poultry units. Avoid combination with strong oxidizing disinfectants in the drinking water line; residual chlorine above 2 ppm can oxidize the active marker and produce a visible color shift within 4 h.

If a Parenteral Route Is Specified, What Filtration Train and Pyrogen Limits Govern the Line?

Parenteral manufacturing of botanical-derived APIs requires a different risk hierarchy than oral dosage forms because the bacterial endotoxin burden, visible particulate load, and pH-dependent precipitation behavior of polyphenolic constituents cannot be corrected after terminal sterilization. The API addition level in a small-volume injectable solution is maintained at 0.5 wt/vol% to 1.5 wt/vol% of the finished solution, with the vehicle composed of Water for Injection, 10–20 vol% propylene glycol, 0.1–0.3 wt/vol% sodium metabisulfite as antioxidant, and sufficient hydrochloric acid or sodium hydroxide to achieve a final pH of 4.5–5.5; published data for this specific configuration is limited, and compatibility studies must be generated for each API lot because the acid-insoluble fraction varies with harvesting season. The process line typically includes a 0.45 µm polyether sulfone pre-filter, a 0.22 µm PVDF sterilizing-grade membrane filter, and an in-line 0.1 µm endotoxin reduction filter for small-volume fills; the filling occurs in an ISO 14644-1 Class 5 aseptic environment under unidirectional airflow, with the stoppers and vials depyrogenated in a 250 °C tunnel for ≥30 min and the solution held at 2–8 °C during filtration to reduce microbial proliferation. The main release tests are CVP 2020 General Chapter 0102 for injectable dosage forms, including bacterial endotoxins at ≤0.5 EU/mL, visible particulates by the light obscuration method, and sub-visible particulates at ≥10 µm and ≥25 µm counts per container; if the preparation is marketed in the European Union, the European Pharmacopoeia monograph for parenteral preparations applies. Terminal finished product types are 10 mL, 20 mL, and 50 mL amber Type I glass vials sealed with bromobutyl rubber stoppers, typically packed in 10-vial trays for veterinary clinic use. The operational boundary is narrow: sterile filtration must be completed within 4 h of bulk solution compounding because the polyphenolic fraction can form colloidal aggregates that raise the clogging load on the 0.22 µm membrane; mixing vessels and transfer lines are cleaned with 1% sodium hydroxide solution and rinsed with pyrogen-free water between batches.

Capsule-Filling Operations and Moisture Uptake Control in Small-Batch Veterinary Compounding

Gelatin capsule filling with the API is performed under controlled relative humidity because the extract powder absorbs moisture from the air and can dissolve the gelatin shell at the filling station. The API addition ratio in a hard gelatin capsule blend is typically 5.0–8.0 wt%, with the remainder consisting of 45–55 wt% pregelatinized starch, 15–20 wt% microcrystalline cellulose PH101, 1–2 wt% colloidal silicon dioxide, and 0.5–1.0 wt% magnesium stearate; the blend is processed in a 300 L tumble blender at 25 rpm for 20 min and then filled into size 0 or size 1 hard gelatin capsules at 25,000–50,000 capsules/h on an intermittent-motion capsule filler. The production room is maintained at 35–40% RH and 18–22 °C, and the capsule shells are conditioned for 12–24 h before filling to prevent brittleness or deformation. On small-batch lines, a recurring failure is powder build-up on the dosing disc and the formation of electrostatic agglomerates when the API is over-dried below 2% moisture; this is managed by adding 0.3–0.5 wt% sodium lauryl sulfate as a charge-control agent in the dry blend. The applicable standards are CVP 2020 General Chapter 0103 for capsules, ISO 9001:2015 for batch release documentation, and USP <795> for non-sterile compounding when the capsules are prepared in a veterinary pharmacy. Terminal finished product types are 250 mg, 500 mg, and 750 mg capsules in 60-count or 100-count high-density polyethylene bottles with desiccant inserts, for companion animal and equine use. Incompatibility with hygroscopic fillers such as mannitol under high shear should be evaluated case by case; published data for this specific configuration is limited.

The release matrix below consolidates critical control parameters for the finished dosage forms discussed above; values refer to product specifications, not API acceptance criteria.

Fluid-bed granulation converts the extract powder into free-flowing granules suitable for oral top-dressing, drench mixing, and single-dose sachet filling. The API addition level in the granulated formulation is usually 4.0–6.0 wt% of the dry granule mass, with the remainder composed of 50–60 wt% sucrose or maltodextrin, 10–15 wt% lactose monohydrate, 5–10 wt% povidone K-30 as the binder solution, and 3–5 wt% microcrystalline cellulose as a disintegrant; the binder solution is prepared as a 10–15 wt% aqueous povidone concentration and sprayed at 1.0–1.5 kg/min onto a 500 kg top-spray fluid-bed granulator with inlet air at 55–65 °C and exhaust air at 30–40 °C. The granulation endpoint is determined by a combination of product temperature 35–40 °C, outlet air humidity ≤20%, and moisture content 2.5–4.0 wt%; after drying, the granules are sieved through 20-mesh and 60-mesh screens to retain a target particle size fraction between 250 µm and 850 µm. A practical processing bottleneck on top-spray fluid beds is the formation of torroidal dead zones near the bottom screen when the fluidization velocity drops below 1.5 m/s; this causes twin peaks in the granule size distribution and requires manual paddle agitation or a Wurster insert. Compliance is anchored to CVP 2020 General Chapter 0104 for granules, GB/T 16764-2006 for feed hygiene, and EU Regulation 2019/6 for medicated feedingstuff granules when the product is used in food-producing species. Terminal finished product types are 15 g single-dose sachets for piglet drenches, 100 g and 250 g jars for top-dress use in weaned pigs, and 1 kg bulk pouches for calf oral rehydration admixture. The granulated form is less dusty than direct powder blends, but it should not be compressed into tablets without re-granulation because the friable granules contain a high proportion of fines after extended pneumatic conveying.